natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 7, wherein the water-insoluble, water-permeable film-forming polymer is ethylcellulose, the water-soluble polymer is polyvinylpyrrolidone and the plasticizer is dibutyl sebacate and/or wherein the core comprises a lubricant, a binder, a glidant, or any combination thereof and/or wherein the carrier comprises an adjuvant, a preservative, an antioxidant, a thickening agent, a chelating agent, an antifungal agent, an antibacterial agent, an isotonic agent, a flavoring agent, a sweetening agent, an anti-foaming agent, a colorant, a diluent, a moistening agent, a parietal cell activator, or a combination thereof. 
Farmaceutski sastav prema zahtjevu 8, gdje je u vodi netopljivi, vodo-propusni film-formirajući polimer etilceluloza, u vodi topljivi polimer je polivinilpirolidon te je plastifikator dibutil sebakat i/ili gdje jezgra sadrži lubrikant, vezivo, glidant, ili bilo koju njihovu kombinaciju i/ili gdje nosač sadrži adjuvans, konzervans, antioksidans, zgušnjivač, kelirajući agens, antigljivični agens, antibakterijski agens, izotonični agens, agens s aromom, zaslađujući agens, agens protiv pjenjenja, bojilo, razrjeđivač, ovlaživač, aktivator parijetalnih stanica, ili njihovu kombinaciju.
Incorporation of the novel omeprazole salts of the present invention in pharmaceutical preparations is exemplified in the following examples. 
Inkorporiranje novih omeprazol soli iz predmetnog izuma u farmaceutske kompozicije je prikazano slijedećim primjerima.
The method of Claim 1 wherein the parasitic invertebrate pest is a fly, mosquito, mite, tick, louse, flea, true bug or maggot, preferably wherein the animal to be protected is a cat or dog and the parasitic invertebrate pest is a flea, tick or mite. 
Uporaba prema zahtjevu 7, naznačena time, da se kod životinje koja se treba zaštititi, radi o mački ili psu, a parazitni štetočina beskičmenjak je buha, krpelj ili rastoč.
The method of claim 10, further comprising the step of: f) further filtration of the filtered fluid obtained in step e1) with a fourth filter with a smaller pore size than that of the third filter, wherein the pore size of the fourth filter is in the range 0.05 um to 2 um. 
Postupak prema bilo kojem zahtjevu 10 ili zahtjevu 11, dodatno obuhvaća korak: f) dodatno filtriranje filtrirane tekućine dobivene u koraku e1) ili e2) upotrebom četvrtog filtra koji ima manju veličinu pora od trećeg filtra, pri čemu je veličina pora trećeg filtra u rasponu od 0.05 µm do 2 µm.
is pyridinyl, pyrimidinyl, oxazolyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C1-C4 alkyl. 
R* je piridinil, pirimidinil, oksazolil ili tiazolil, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen i C,-Ca alkil.
one or more antigen(s) selected from the group consisting of: diphtheria toxoid; tetanus toxoid; hepatitis B virus surface antigen; an inactivated poliovirus antigen; one or more acellular pertussis antigens; a conjugate of the capsular saccharide antigen from H.influenzae type B; a conjugate of the capsular saccharide antigen from serogroup C of N.meningitidis; a conjugate of the capsular saccharide antigen from serogroup Y of N.meningitidis; a conjugate of the capsular saccharide antigen from serogroup W135 of N.meningitidis; and a conjugate of the capsular saccharide antigen from serogroup A of N.meningitidis; or a temperature protective agent. 
jedan ili više antigena koje se bira iz skupine koju čine: difterijski toksoid; tetanusni toksoid; površinski antigen iz virusa hepatitisa B; antigen iz inaktiviranog poliovirusa; jedan ili više beszaničnih antigena iz uzročnika hripavca; konjugat kapsularnog saharidnog antigena iz bakterije H. influenzae tip B; konjugat kapsularnog saharidnog antigena iz seroskupine C bakterije N. meningitidis; konjugat kapsularnog saharidnog antigena iz seroskupine Y bakterije N. meningitidis; konjugat kapsularnog saharidnog antigena iz seroskupine W135 bakterije N. meningitidis; i konjugat kapsularnog saharidnog antigena iz seroskupine A bakterije N. meningitidis; ili sredstvo za zaštitu od temperatura koje poboljšava toplinsku stabilnost pripravka.
is R26 substituted with R30, which is substituted with CH2R37 or CH(R31)(R37); 
je alkil koji je nesupstituiran ili supstituiran s R36;
moving the plant along the cutting devices for the purpose of removing the leaves. 
pomicanje biljke uzduž reznih uređaja radi uklanjanja lišća.
A dispenser according to claim 5, wherein the substance source is a pressurised metered-dose inhaler (pMDI). 
Dispenzer sukladno zahtjevu 18, naznačen time da je izvor supstance inhalator odmjerenih doza pod pritiskom (PMDI).
In order to check the contribution of the Ig-like domain within the r-hIL6-IL6R chimera to the binding to the MEP HYPERCEL® column, binding of IL-6 alone to the Mep HYPERCEL® column was explored. 
Kako bi se procijenio doprinos Ig-slične domene prisutne unutar r-hIL6-IL6R na vezanje na kolonu MEP HyperCel, ispitano je vezanje samog IL-6 na kolonu MEP HyperCel.
The process of claim 1, wherein the multi-component gas stream comprises natural gas, coal gas, refinery gas or gas from chemical plants. 
Proces prema patentnom zahtjevu 9, naznačen time, da višekomponentna plinska struja sadrži prirodni plin, gradski plin, rafinerijski plin ili plin iz kemijskih postrojenja.
The compound for use according to anyone of the preceding claims, wherein the compound is used in a pharmaceutical composition further comprising dimethyl isosorbide. The compound for use according to claim 11 in the form of a topical formulation. A compound selected from compounds having the following formula: wherein 
Spoj za uporabu prema bilo kojem od prethodnih zahtjeva, u kombinaciji sa spojem izabranim iz grupe koja obuhvaća inhibitore 5a-reduktaze koji nisu spojevi prema zahtjevu 1, i anti-androgene. Farmaceutski oblik za uporabu u prevenciji i/ili liječenju karcinoma prostate, oblik sadrži kombinaciju dimetil izosorbida i spoj izabran između spojeva koji imaju sljedeću formulu:
an oxidation reaction to obtain: optionally followed by a second oxidation to obtain the following compound: wherein: 
No NO2 ini: i zatim, prema potrebi, drugoj oksidaciji, čime se dobije slijedeći spoj:
The floatable modular device of claim 8 or 9, wherein the at least one connector (5) element includes connecting structure configured to support the plural ones of the cages (3) in a non-coplanar, face-on manner as a stack, in which stack the peripheral regions of the mutually adjacent cages form a corrugated envelope. 
Uređaj iz zahtjeva 1, unutar kojeg najmanje jedan spojni element uključuje priključnu strukturu koja je postavljena kako bi podržavala veći broj kaveza kao skup, unutar kojeg periferna područja susjednih kaveza tvore valoviti omotač.
Method according to claim 19, characterised in that the immunoglobulin is a murine immunoglobulin selected from the group consisting of IgA, IgD, IgE, IgG1, IgG2A, 1gG2B, IgG2C, IgG3: and IgM. 
Postupak u skladu sa zahtjevom 19, naznačen time, da imunoglobulin je mišji imunoglobulin izabran iz skupine koju čine IgA, IgD, IgE, IgG1, IgG2A, IgG2B, IgG2C, IgG3 i IgM. .
Examples of suitable anti-hypertensive agents for use in combination with the compound of the present invention include beta adrenergic blockers, calcium channel blockers (L-type and T-type; e.g. 
Primjeri pogodnih anti-hipertenzivnih sredstava za primjenu u kombinaciji sa spojem prema ovom izumu obuhvaćaju beta adrenergične blokatore, blokatore kalcijevih kanala (L-tipa i T-tipa; npr.
is phenyl, R2 is hydrogen, R3 is chloro and R4 is hydroxy, hydroxymethyl or methoxymethyl; 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što R* je hidroksi, hidroksimetil ili metoksimetil.
Published International application No. 
Broj međunarodne prijave:
After filtration, the procedure is repeated overnight, thereafter, the resin is filtered and washed with toluene and dichloromethane. 
Nakon filtracije, postupak se ponovi preko noći, a zatim se smola filtrira i ispere toluenom i diklorometanom.
A compound of claims 21, 22, 23 or 24, wherein ring vertex c is N. 
Spoj u skladu s patentnim zahtjevom 21, 22, 23 ili 24, naznačen time, da je vrh prstena c N.
the alcohol of the general formula VI is substituted to the corresponding derivative of the general formula VII, 
VI, gdjen=5do9 alkohol opće formule VI se supstitucijom pretvara u odgovarajući derivat opće VII,
The residue is loaded on a pre-packed Isolute™ silica column and eluted with DCM/MeOH (100:0 increasing to 98:2) to yield the titled compound as a yellow powder. 
Ostatak se stavi na pred-pakirani Isolute" stupac silika gela i ispere se s DCM/MeOH (100:0 rastući do 98:2), čime se dobije naslovni spoj kao žuti prah.
Curing of the Resin Base of a Dental Filling Material by Means of Ultrasound 
Očvršćivanja baze za smolu za materijal za dentalno punilo pomoću ultrazvuka
A maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine to be administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); 
(11) period održavanja pri čemu da se primjenjuje Kladribin i pri čemu ukupna doza Kladribina koja se daje tijekom perioda održavanja je niža od ili jednaka ukupnoj dozi Kladribina dosegnutoj na završetku perioda indukcije (1);
The dosage of buprenorphine may vary according to a variety of factors such as underlying disease states, the individual's condition, weight, and age. 
HR P20070476 T3 Doziranje buprenorfina može varirati u skladu s raznim činiocima kao što su oboljenja, stanje pojedinca, tjelesna težina i dob.
the co-crystal is administered with etoposide, doxorubicin, daunorubicin, epirubicin or bleomycin. 
sukristal se primijenjuje uz etopozid, doksorubicin, daunorubicin, epirubicin ili bleomicin.
B is selected from the group consisting of - CN -NR5R6; -CONR5R6; -NHCONR5R6 
B je odabran iz skupine koja se sastoji od: [image] pri čemu je
The compound for use according to claim 7, wherein the pharmaceutical composition is in the form of a topical formulation. 
Farmaceutski oblik za uporabu prema zahtjevu 10 ili 11 u topikalnom obliku.
shows the system of Figure 2 in a state, in which a capsule has reached its closing position between a bell member and the capsule holder, 
prikazuje sustav iz slike 2 u položaju u kojemu je čahura postigla svoj zatvoreni položaj između zvonastog elementa i držača čahure,
The aqueous agrochemical suspension composition comprising 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole, at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin, an inorganic thickener and a dispersant shows excellent efficacy. TECHNICAL FIELD 
Vodena agrokemijska suspenzija koja sadrži 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5- dihidrooksazol kao aktivni sastojak, barem jednu vrstu alkohola odabranu iz grupe koja se sastoji od etilen glikola, propilen glikola 1 glicerina, neorgansko sredstvo za zgušnjavanje i disperzirajuće sredstvo, gdje barem jedna vrsta alkohola sadrži propilen glikol.
Method according to claim 11, characterized in that the pivot point (12a,12b) of the pivoted lever (11) is fixed by forcing the secondary pivoting (15) arm against a fixed stop (18a, 18b). 
Postupak prema zahtjevu 11, naznačen time, da se učvršćuje stožerna točka (12a, 12b) stožerne poluge (11) pomoću prisiljavanja pomoćne stožerne ručice (15) prema učvršćenom zaporu (184, 18b). t>&
The siRNA according to claim 1 or 2, wherein 1 to 10 consecutive nucleotides from the 5' terminus of the antisense strand of the siRNA are converted into DNA. 
siRNA u skladu sa zahtjevom 1 ili 2, naznačena time, da se 1 do 10 uzastopnih nukleotida iz 5' terminusa antisens lanca siRNA pretvaraju u DNA.
A pharmaceutical composition comprising: (1) a compound of the formula: or a pharmaceutically acceptable salt thereof, and (2) a NS5B polymerase inhibitor, for use in combination with a NS3 protease inhibitor in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder. 
DOTA A (D 2 KE njegovu farmaceutski prihvatljivu sol, i (2) NS5B polimerazni inhibitor, za primjenu u kombinaciji sa NS3 proteaznim inhibitorom u profilaktičkom ili terapijskom liječenju hepatitisa C ili poremećaja povezanog sa hepatitisom €.
the sum total of the 5' and the 3' homology arms of the LTVEC is from about 10 kb to about 150 kb; or 
zbroj ukupnih 5' i 3' homolognih dijelova LTVEC-a je od oko 16 kb do oko 150 kb.
The method as claimed in claim 1, further comprising removing the precipitate from the first surface of the filter band by scraping. 
Postupak prema zahtjevu 1, naznačen time da se talog uklanja s prve površine trake za filtriranje (122, 122', 122) struganjem.
Recurrent vulvovaginal candidiasis (VVC) may be defined as at least four mycologically proven symptomatic episodes in the previous 12 months with exclusion of other common vaginal pathogens. 
Recidivna vulvovaginalna kandidijaza (VVC) može se odrediti kao najmanje četiri mikološki dokazane simptomatske cpizodc u prethodnih 12 mjeseci uz izuzimanje drugih uobičajenih vaginalnih patogena.
One more preferred class of alkyl and alkoxy groups has from 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms. 
Još jedna poželjnija klasa alkil i alkoksi grupa ima od 1 do oko 6 atoma ugljika, a najpoželjnije 1, 2, 3 ili 4 atoma ugljika.
The process according to claim 1, characterised in that the flue gases (A) are denoxed to at least 60 %. 
Postupak prema jednom zahtjevu od 1 do 4, naznačen time da su dimni plinovi (A) denitrificirani do barem 60%.
4,686,237, octahydronaphthalenes, such as disclosed in U.S. Patent No. 
4,686,237, oktahidronaftaleni, kao što je navedeno u U.S. Patentu br.
The process according to claim 5 wherein said compound of formula II is present at an amount of about 0.025 molar. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što je navedeni spoj Formule II prisutan u količini od 0,025 mol.
at least one mobile suction means, which moves through the bottom of said at least one containing means suctioning the water flow containing the settled particles; 
najmanje jedno pokretno usisno sredstvo (5), koje se kreće po dnu (17) navedenog najmanje jednog sredstva za držanje (8) gdje usisava struju vode koja sadrži nataložene čestice;
Combination for use according to claim 1 where the inflammatory disease is a respiratory disease selected from asthma or COPD, rheumatism or an auto-immune disease selected from rheumatoid arthritis, glomerulonephritis, multiple sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus or psoriasis. 
4. Kombinacija sukladno patentnom zahtjevu 2, naznačena time, da je autoimuna bolest reumatoidni artritis, glomeruloneftitis, multipla skleroza, Crohnova bolest, ulcerozni kolitis, sistemski lupus eritematosus ili psorijaza.
Primycin or a primycin component represented by the following general formula (I) wherein R1 is n-butyl, n-pentyl or n-hexyl and R2 is arabinosyl, H or OH, which primycin component is in basic form or in salt form, or a combination of said primycin components for use in the treatment or prevention of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative Staphylococcus sp. 
Primicin ili komponenta primicina predstavljeni sljedećom općenitom formulom (I) [image] gdje R1 je n-butil, n-pentil ili n-heksil i R2 je arabinozil, H ili OH, koja komponenta primicina je u bazičnom obliku ili obliku soli, ili kombinacija te komponente primicina za uporabu u liječenju ili prevenciji infekcija uzrokovanih meticilin-rezistentnim Staphilococcus aureus (MRSA), meticilin-rezistentnim koagulaza-negativnim Staphilococcus sp.
a pyridyl group optionally mono- or poly-substituted with a sulphanyl group, 
piridilna skupina koja može biti mono ili višesupstituirana sulfanilnom skupinom,
The process according to one of the preceding claims, wherein the water to be purified is selected from industrial waste water, drinking water, urban waste water, waste water from breweries or other beverage industries, or water in the paper industry. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je voda koju treba pročistiti izabrana od industrijske otpadne vode, vode za piće, urbane otpadne vode, otpadne vode iz pivovara ili drugih industrija pića, ili vode u industriji papira.
The pharmaceutical composition according to claim 14 in form of a tablet, capsule, powder, pellet, suspension, emulsion, solution, cream, gel, ointment, lotion or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
An antibody or antigen-binding fragment thereof, which binds human IL-6 receptor (hIL-6R) with a KD of 500 pM or less, as measured by surface plasmon resonance. 
Antitijelo ili njegov fragment koji se veže na antigen, koji se specifično veže na humani interleukin-6 receptor (hIL-6R) s konstantom KD od 500 pM ili manjom izmjereno površinskom plazmonskom rezonancijom, naznačeno time, da CDR teškog lanca i CDR lakog lanca sadržavaju: (i)
Gasification reactor according to claim 9, characterised in that the height (h2) of the inlet (3) for feeding organic solid, measured in metres from the junction of the cylindrical section with the frustoconical section, is equal to the sine of angle B measured in degrees: h2= sinB. 
Reaktor za rasplinjavanje u skladu s patentnim zahtjevom 9, naznačen time što visina (h2) ulaza (3) za dodavanje organskog čvrstog materijala, izmjerena u metrima od spoja valjkastog odjeljka s odjeljkom u obliku krnjeg stošca, je jednaka sinusu kuta B izmjerenog u stupnjevima: h2 = sinB.
10 shows the details of the connection of the receiver to the transducer or other device that produces the acoustic signal. 
Slika 10 prikazuje pojedinosti priključka prijemnika na davač ili drugi uređaj koji proizvodi zvučni signal.
placing a form in a field of view of a camera, wherein the form includes thereon at least a first fiducial mark and a second fiducial mark, and wherein each of the first fiducial mark and the second fiducial mark has a measurable property that is essentially scale invariant; 
Postupak detektiranja korisničkih oznaka, naznačen time što se sastoji u: stavljanje formulara (400, 700) u vidno polje kamere, gdje formular (400, 700) u sebi sadrži u najmanju ruku prvu položajnu oznaku i druga položajnu oznaku (401b, 701b);
A compound selected from or a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof. 
Spoj naznačen time da je odabran od [image] ili [image] njihova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njihov kvaternarni amin, njihov stereokemijski izomerni oblik, njihov tautomerni oblik ili njihov N-oksidni oblik.
The process according to claim 1 wherein said lipase from Candida is Candida cylindracea (CCL) or Candida antartica of type B (CALB). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedena lipaza iz kvasca Candida lipaza iz kvasca Candida cylindracea (CCL) ili Candida antartica tip B (CALB).
The pharmaceutical composition according to claim 25, which is for use against lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastrointestinal stromal tumor, uterine cervix cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, or sarcoma. 
Farmaceutska kompozicija u skladu sa patentnim zahtjevom 14, za primjenu u liječenju raka pluća, urotelijalnog raka, kolorektalnog raka, raka prostate, raka jajnika, raka gušterače, raka dojke, raka mokraćnog mjehura, raka želuca, gastrointestinalnog stromalnog tumora, raka grlića materice, raka jednjaka, karcinoma pločastih stanica, peritonealnog raka, raka jetre, hepatocelularnog raka, raka debelog crijeva, raka rektuma, kolorektalnog raka, raka endometrija, raka materice, raka žlijezda slinovnica, raka bubrega, raka vulve, raka štitnjače, raka penisa, leukemije, malignog limfoma, plazmacitoma, mijeloma, ili sarkoma.
identifies a maximum in said cross-correlations values as corresponding to a time of arrival of said current pulse of output ultrasonic vibrations; or 
(ii) identificira maksimum u navedenim vrijednostima unakrsnih korelacija kao odgovarajući vremenu dolaska navedenog trenutnog impulsa izlaza ultrazvučnih vibracija; ili
The cis -dihydrotetrabenazine used in the present invention is 3,11 b, cis-dihydrotetrabenazine. 
Cis-dihidrotetrabenazin koji se koristi u ovom izumu je (+) 3,11b, cis-dihidrotetrabenazin.
The antibody according to claim 13, wherein said contacting or said administrating is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
protutijelo je pogodno za davanje najmanje jednim načinom davanja koji je odabran od parenteralnog, subkutanog, intramuskularnog, intravenoznog, intraartikularnog, intrabronhijalnog, intraabdominalnog, intrakapsularnog, intrahrskavičnog, intrakavitarnog, intracelijalnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastričnog, intrahepatičnog, intramiokardijalnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatskog, intrapulmonalnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratoraksnog, intrauterinog, intravezikalnog, intralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog, i transdermalnog načina davanja; ili
This recess 4 is also formed on all four sides of the wall element 2. 
Ovo udubljenje 4 je također oblikovano na sve četiri strane zidnog elementa 2.
neurological diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
(x1i) neuroloških bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
A compound according to any preceding claim wherein 
Spoj u skladu sa patentnim zahtjevom 2 naznačen time, da zbroj m+r je 1.
The mouse of claim 1, wherein the λ light chain allele comprises a contiguous sequence of the human λ light chain locus that spans from Vλ3-27 to Vλ3-1 and a contiguous sequence of the human λ light chain locus that spans from Vλ5-52 to Vλ1-40. 
graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ5- 52 do hVλ1-40 i graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ3-29 do hVλ3-1.